
                                                                    EXHIBIT 99.1

FOR IMMEDIATE RELEASE

Contact:
Gregory A. Marsh                                   Michelle D. Getty
Vice President & CFO                               Investor Relations
AmeriPath, Inc.                                    AmeriPath, Inc.
561-712-6211                                       561-712-6260
                                                   E-mail: invrel@ameripath.com


             AMERIPATH, INC. ANNOUNCES AMENDMENT TO CREDIT AGREEMENT

Riviera Beach, FL, April 5, 2001 - AmeriPath, Inc. (Nasdaq:PATH), the largest
physician and laboratory company focused on providing anatomic pathology, cancer
diagnostic, genomics, and healthcare information services, today announced that
it has amended its credit facility with the syndicate of banks led by Fleet
National Bank.

The amendment was executed March 29, 2001, and provides the Company with the
ability to record charges, in excess of those previously approved by the
lenders, in connection with the acquisition of Inform DX, without impacting
future covenant compliance. These additional charges were disclosed in the
Company's press release dated February 27, 2001. The Company expects the
charges, totaling approximately $7.2 million, to be recorded in the first
quarter of 2001. These charges resulted from the formalization of the Inform DX
integration plans and increased the synergy estimates from $3.0 million to more
than $5.0 million per year.

The amendment increased the Company's interest rate by 37.5 basis points. Since
the Company's interest rate is tied to the prime rate or LIBOR, we believe that
the increase will be mitigated by the recent rate reductions put in place by the
Federal Reserve Board. As consideration for the amendment, the Company will be
required to pay an amendment fee of up to 30 basis points to lenders that
consent to the amendment. This fee will be charged to the merger costs in the
first quarter of 2001. The entire amendment will be filed on Form 8-K on April
6, 2001.

Chairman and Chief Executive Officer, James C. New, stated, "We are pleased to
announce the amendment to our credit agreement. Although the amendment came with
some additional cost, its execution clears the way for us to continue the
integration of Inform DX's operations with AmeriPath. These charges were
essential to accomplishing the most effective integration plan and, as a result,
our annual synergy estimates have increased from our original estimate of $3.0
million to $5.0 million. Once again, our syndicate of banks, led by Fleet and
Bank of America, has provided us with the flexibility necessary to exceed our
original goals."

AmeriPath, Inc. is the nation's largest company focused on providing anatomic
pathology, cancer diagnostics, genomics, and physician and laboratory healthcare
information services to physicians, hospitals, national clinical laboratories
and managed care organizations. The Company's 425 physicians provide medical
services through 42 outpatient pathology laboratories, 224 hospital inpatient
laboratories, and 64 outpatient surgery centers in 21 states.

                                     -more-
<PAGE>

         The statements contained in this press release may include
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, and are based on management's current beliefs and
expectations. Past performance is not necessarily indicative of future results.
In addition, forward-looking statements - which are identified by words such as
"may", "should", "believe", "expect", "anticipate", "estimate" and similar
expressions - as well as any financial and operating estimates, forecasts and/or
projections, are subject to a number of risks and uncertainties, many of which
involve factors or circumstances which are beyond the Company's ability to
control. These factors, risks and uncertainties could cause actual results to
differ materially from historical results or those expected, estimated or
anticipated. These include factors, risks and uncertainties relating to general
economic conditions; competition and changes in competitive factors; the extent
of success of the Company's operating initiatives and growth strategies, federal
and state healthcare regulation (and compliance); reimbursement rates under
government-sponsored and third party healthcare programs and the payments
received under such programs; changes in coding; changes in technology;
dependence upon pathologists and contracts; the ability to attract, motivate,
and retain pathologists; labor and technology costs; marketing and promotional
efforts; the availability of pathology practices in appropriate locations that
the Company is able to acquire on suitable terms or develop; the successful
completion and integration of acquisitions (and achievement of planned or
expected synergies); access to sufficient amounts of capital on satisfactory
terms; and tax laws. The forward looking statements included in this press
release are made as of the date hereof, and the Company undertakes no obligation
to update or revise any such statements, whether as result of new developments,
new information or otherwise. Further information regarding risks, uncertainties
and other factors that could affect the Company's financial or operating
results, or which could cause actual results to differ materially from those
expected, estimated or anticipated, are included in the Company's annual report
on Form 10-K for the year ended December 31, 2000 and subsequent filings with
the SEC.

Editor's Note: This release is also available at http://www.ameripath.com

